PMID- 17352871
OWN - NLM
STAT- MEDLINE
DCOM- 20080314
LR  - 20210103
IS  - 1672-1977 (Print)
IS  - 1672-1977 (Linking)
VI  - 5
IP  - 2
DP  - 2007 Mar
TI  - [Inhibition action of bufalin on human transplanted hepatocellular tumor and its 
      effects on expressions of Bcl-2 and Bax proteins in nude mice].
PG  - 155-9
AB  - OBJECTIVE: To investigate the anti-tumor effect of bufalin and its regulation on 
      Bcl-2 and Bax proteins in orthotopically transplanted tumor of human 
      hepatocellular carcinoma in nude mice. METHODS: Orthotopically transplanted tumor 
      of human hepatocellular carcinoma was established in nude mice. The mice were 
      randomly divided into five groups: high-dose bufalin-treated group (1.5 mg/kg), 
      medium-dose bufalin-treated group (1 mg/kg), low-dose bufalin-treated group (0.5 
      mg/kg), adriamycin-treated group (8.0 mg/kg), and normal saline-treated group. 
      After 25 days, mice were sacrificed. The tumor volume was measured, and the 
      pathological changes of tumor tissues were detected by HE staining to observe the 
      tumor necrosis degree. Cell morphological changes were also observed by an 
      electron microscopy. Label index of tumor cell apoptosis was assessed by terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), and the 
      expressions of Bcl-2 and Bax proteins were determined by immunohistochemical 
      method. RESULTS: The tumor volume in the bufalin-treated groups was shrunk 
      significantly compared with that in the normal saline-treated group (P<0.01). The 
      survival time of the bufalin-treated groups was prolonged compared with that of 
      the adriamycin-treated group and the normal saline-treated group P<0.05. 
      Apoptotic characteristics could be seen in tumor tissues of the bufalin-treated 
      groups. The label index of tumor cell apoptosis in the bufalin-treated groups 
      (5.87+/-2.13, 8.86+/-2.96 and 10.60+/-3.42 in low-, medium- and high-dose groups 
      respectively) was higher than that in the adriamycin-treated group (3.28+/-0.98) 
      (P<0.05, P<0.01). The expression of Bax was up-regulated, while no changes were 
      detected as to Bcl-2 protein in tumors of the bufalin-treated groups. CONCLUSION: 
      Bufalin has significant anti-tumor effect on the orthotopically transplanted 
      tumor of human hepatocellular carcinoma in nude mice. Its effect might be related 
      to up-regulation of Bax protein and inducement of the tumor cell apoptosis.
FAU - Gu, Wei
AU  - Gu W
AD  - Department of Traditional Chinese Medicine, Changhai Hospital, Second Military 
      Medical University, Shanghai 200433, China.
FAU - Han, Ke-qi
AU  - Han KQ
FAU - Su, Yong-hua
AU  - Su YH
FAU - Huang, Xue-qiang
AU  - Huang XQ
FAU - Ling, Chang-quan
AU  - Ling CQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhong Xi Yi Jie He Xue Bao
JT  - Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
JID - 101199657
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bufanolides)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 80168379AG (Doxorubicin)
RN  - U549S98QLW (bufalin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Bufanolides/*pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Doxorubicin/pharmacology/therapeutic use
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Nick-End Labeling
MH  - Liver Neoplasms, Experimental/metabolism/pathology/*prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Phytotherapy
MH  - Proto-Oncogene Proteins c-bcl-2/*biosynthesis
MH  - Random Allocation
MH  - Survival Analysis
MH  - *Xenograft Model Antitumor Assays
MH  - bcl-2-Associated X Protein/*biosynthesis
EDAT- 2007/03/14 09:00
MHDA- 2008/03/15 09:00
CRDT- 2007/03/14 09:00
PHST- 2007/03/14 09:00 [pubmed]
PHST- 2008/03/15 09:00 [medline]
PHST- 2007/03/14 09:00 [entrez]
AID - 674 [pii]
AID - 10.3736/jcim20070211 [doi]
PST - ppublish
SO  - Zhong Xi Yi Jie He Xue Bao. 2007 Mar;5(2):155-9. doi: 10.3736/jcim20070211.